REFERENCES

1. Fouad MA, Abdel-Hamid H, Ayoup MS. Two decades of recent advances of Ugi reactions: synthetic and pharmaceutical applications. RSC Adv 2020;10:42644-81.

2. Nagarajaiah H, Mukhopadhyay A, Moorthy JN. Biginelli reaction: an overview. Tetrahedron Lett 2016;57:5135-49.

3. Zheng X, Liu W, Zhang D. Recent advances in the synthesis of oxazole-based molecules via van leusen oxazole synthesis. Molecules 2020;25:1594.

4. Wang L, Woods KW, Li Q, et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002;45:1697-711.

5. Kemnitzer W, Kasibhatla S, Jiang S, et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions. Bioorg Med Chem Lett 2005;15:4745-51.

6. Kemnitzer W, Drewe J, Jiang S, et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions. J Med Chem 2007;50:2858-64.

7. Schmitt F, Gold M, Rothemund M, et al. New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. Eur J Med Chem 2019;163:160-8.

8. Schmitt F, Schobert R, Biersack B. New pyranoquinoline derivatives as vascular-disrupting anticancer agents. Med Chem Res 2019;28:1694-703.

9. Dell CP, Singh JP, Smith CW. Pharmaceutical Compounds. Pat. No. US005284868 A (1994).

10. Wood DL, Panda D, Wiernicki TR, Wilson L, Jordan MA, Singh JP. Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181. Mol Pharmacol 1997;52:437-44.

11. Yusenko MV, Biyanee A, Frank D, et al. Bcr-TMP, a novel nanomolar-active compound that exhibits both MYB- and microtubule-inhibitory activity. Cancers (Basel) 2021;14:43.

12. Cicirò Y, Sala A. MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis 2021;10:19.

13. Köhler LHF, Reich S, Begemann G, Schobert R, Biersack B. 2-Amino-4-aryl-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitriles with microtubule-disruptive, centrosome-declustering, and antiangiogenic effects in vitro and in vitro. ChemMedChem 2022;17:e202200064.

14. Cai SX, Zhang H, Jiang S, Storer R. Preparation of substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and their uses against cancer and other disorders. Pat. No. WO2002092594 (2002).

15. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metast Rev 2001;20:3-11.

16. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307-18.

17. Chayka O, Kintscher J, Braas D, Klempnauer KH. v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter. Mol Cell Biol 2005;25:499-511.

18. Yusenko M, Jakobs A, Klempnauer KH. A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity. Sci Rep 2018;8:13159.

19. Lau VM, Pfalzgraff WC, Markland TE, Kanan MW. Electrostatic control of regioselectivity in Au(I)-catalyzed hydroarylation. J Am Chem Soc 2017;139:4035-41.

20. Köhler LHF, Reich S, Yusenko M, et al. A new naphthopyran derivative combines c-myb inhibition, microtubule-targeting effects, and antiangiogenic properties. ACS Med Chem Lett 2022;13:1783-90.

21. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999;40:301-6.

22. Biersack B, Muthukumar Y, Schobert R, Sasse F. Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles. Bioorg Med Chem Lett 2011;21:6270-3.

23. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009;15:2594-601.

24. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc 2010;5:628-35.

25. Cross LM, Cook MA, Lin S, Chen J, Rubinstein AL. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler Thromb Vasc Biol 2003;23:911-2.

26. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Pharmacol 2008;9:658-71.

27. Gao X, Aguanno D, Board M, Callaghan R. Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer. Biochim Biophys Acta Gen Subj 2021;1865:129915.

28. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3:1119-25.

29. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-7.

30. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011;50:161-78.

31. Scala S, Akhmed N, Rao US, et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 1997;51:1024-33.

32. Lei ZN, Teng QX, Wu ZX, et al. Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm 2021;2:765-77.

33. Su M, Huang J, Liu S, et al. The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4. Sci Rep 2016;6:28139.

34. Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA 1989;86:3379-83.

35. Calabretta B, Sims RB, Valtieri M, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991;88:2351-5.

36. Guérin M, Zheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990;5:131-5.

37. Drabsch Y, Hugo H, Zhang R, et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007;104:13762-7.

38. Biroccio A, Benassi B, D’agnano I, et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer. Am J Pathol 2001;158:1289-99.

39. Hugo H, Cures A, Suraweera N, et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Gene Chromosome Canc 2006;45:1143-54.

40. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Drug resistance in targeted cancer therapies with RAF inhibitors. Cancer Drug Resist 2021;4:665-83.

41. Li Y, Huang Y, Cheng H, et al. Discovery of BRAF/HDAC dual inhibitors suppressing proliferation of human colorectal cancer cells. Front Chem 2022;10:910353.